Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium

Sook Wah Yee; Deanna J. Brackman; Elizabeth A. Ennis; Yuichi Sugiyama; Landry K. Kamdem; Rebecca Blanchard; Aleksandra Galetin; Lei Zhang; Kathleen M. Giacomini

doi:10.1002/cpt.1098

Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium

Sook Wah Yee
, Deanna J. Brackman
, Elizabeth A. Ennis
, Yuichi Sugiyama
, Landry K. Kamdem
, Rebecca Blanchard
, Aleksandra Galetin
, Lei Zhang
, Kathleen M. Giacomini^*

^*Corresponding author for this work

Pharmacy

Research output: Contribution to journal › Article › peer-review

113 Downloads (Pure)

Abstract

Advances in genomic technologies have led to a wealth of information identifying genetic polymorphisms in membrane transporters, specifically how these polymorphisms affect drug disposition and response. This review describes the current perspective of the International Transporter Consortium (ITC) on clinically important polymorphisms in membrane transporters. ITC suggests that, in addition to previously recommended polymorphisms in ABCG2 (BCRP) and SLCO1B1 (OATP1B1), polymorphisms in the emerging transporter, SLC22A1 (OCT1), be considered during drug development. Collectively, polymorphisms in these transporters are important determinants of interindividual differences in the levels, toxicities, and response to many drugs.

Original language	English
Journal	Clinical Pharmacology and Therapeutics
Early online date	21 Apr 2018
DOIs	https://doi.org/10.1002/cpt.1098
Publication status	Published - 2018

Access to Document

10.1002/cpt.1098

Yee et al_CPT mergedAccepted author manuscript, 2 MB

Cite this

@article{fc40af00b85d4368a1f5b4e6ccdabf71,

title = "Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium",

abstract = "Advances in genomic technologies have led to a wealth of information identifying genetic polymorphisms in membrane transporters, specifically how these polymorphisms affect drug disposition and response. This review describes the current perspective of the International Transporter Consortium (ITC) on clinically important polymorphisms in membrane transporters. ITC suggests that, in addition to previously recommended polymorphisms in ABCG2 (BCRP) and SLCO1B1 (OATP1B1), polymorphisms in the emerging transporter, SLC22A1 (OCT1), be considered during drug development. Collectively, polymorphisms in these transporters are important determinants of interindividual differences in the levels, toxicities, and response to many drugs.",

author = "Yee, \{Sook Wah\} and Brackman, \{Deanna J.\} and Ennis, \{Elizabeth A.\} and Yuichi Sugiyama and Kamdem, \{Landry K.\} and Rebecca Blanchard and Aleksandra Galetin and Lei Zhang and Giacomini, \{Kathleen M.\}",

year = "2018",

doi = "10.1002/cpt.1098",

language = "English",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "John Wiley \& Sons Ltd",

}

TY - JOUR

T1 - Influence of Transporter Polymorphisms on Drug Disposition and Response

T2 - A Perspective From the International Transporter Consortium

AU - Yee, Sook Wah

AU - Brackman, Deanna J.

AU - Ennis, Elizabeth A.

AU - Sugiyama, Yuichi

AU - Kamdem, Landry K.

AU - Blanchard, Rebecca

AU - Galetin, Aleksandra

AU - Zhang, Lei

AU - Giacomini, Kathleen M.

PY - 2018

Y1 - 2018

N2 - Advances in genomic technologies have led to a wealth of information identifying genetic polymorphisms in membrane transporters, specifically how these polymorphisms affect drug disposition and response. This review describes the current perspective of the International Transporter Consortium (ITC) on clinically important polymorphisms in membrane transporters. ITC suggests that, in addition to previously recommended polymorphisms in ABCG2 (BCRP) and SLCO1B1 (OATP1B1), polymorphisms in the emerging transporter, SLC22A1 (OCT1), be considered during drug development. Collectively, polymorphisms in these transporters are important determinants of interindividual differences in the levels, toxicities, and response to many drugs.

AB - Advances in genomic technologies have led to a wealth of information identifying genetic polymorphisms in membrane transporters, specifically how these polymorphisms affect drug disposition and response. This review describes the current perspective of the International Transporter Consortium (ITC) on clinically important polymorphisms in membrane transporters. ITC suggests that, in addition to previously recommended polymorphisms in ABCG2 (BCRP) and SLCO1B1 (OATP1B1), polymorphisms in the emerging transporter, SLC22A1 (OCT1), be considered during drug development. Collectively, polymorphisms in these transporters are important determinants of interindividual differences in the levels, toxicities, and response to many drugs.

UR - https://www.scopus.com/pages/publications/85047784627

U2 - 10.1002/cpt.1098

DO - 10.1002/cpt.1098

M3 - Article

AN - SCOPUS:85047784627

SN - 0009-9236

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

ER -

Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium

Abstract

Access to Document

Other files and links

Fingerprint

Cite this